Lihua Zheng

Lihua Zheng

Company: AnHeart Therapeutics

Job title: Chief Business Officer & Co-Founder


Taletrectinib, A Potential Best-In-Class Next-Generation ROS1 Inhibitor, Hits a Unique Balance of Excellent Efficacy & Favorable Safety Profile 12:00 pm

Taletrectinib can be a practice-changing ROS1 inhibitor to meet unmet medical needs Highly selective and potent against ROS1 and secondary resistant mutations as well as excellent intracranial antitumor activity Well-tolerated safety profile with low incidence of CNS adverse eventsRead more

day: Day One

© Copyright 2022 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.